Scolaris Content Display Scolaris Content Display

Study flow diagram
Figures and Tables -
Figure 1

Study flow diagram

'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages
Figures and Tables -
Figure 2

'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages

'Risk of bias' summary: review authors' judgements about each risk of bias item for the included study
Figures and Tables -
Figure 3

'Risk of bias' summary: review authors' judgements about each risk of bias item for the included study

Comparison 1 Adenovirus vaccines versus placebo, Outcome 1 Incidence of the common cold.
Figures and Tables -
Analysis 1.1

Comparison 1 Adenovirus vaccines versus placebo, Outcome 1 Incidence of the common cold.

Summary of findings for the main comparison. Virus vaccines compared to placebo for preventing the common cold in healthy people

Virus vaccines compared to placebo for preventing the common cold in healthy people

Patient or population: healthy people
Settings: outpatients at Great Lakes Naval Training Center
Intervention: virus vaccines for preventing the common cold¹
Comparison: placebo

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No. of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

Placebo

Virus vaccines for preventing the common cold

Incidence of the common cold
Number of participants with common cold by group
Follow‐up: mean 9 weeks

Study population

RR 0.95
(0.45 to 2.02)

2307
(1 study)²

⊕⊕⊝⊝
low³ ⁴

12 per 1000

11 per 1000
(5 to 24)

Vaccine safety

The study stated that there were no adverse events related to the vaccine.

2307
(1 study)²

⊕⊕⊝⊝
low³ ⁵

Mortality related to the vaccine ‐ not reported

See comments

See comments

See comments

See comments

See comments

The included study did not report this outcome.

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio

GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1Adenovirus vaccine used for preventing the common cold.
2Griffin 1970.
3Downgraded one level due to high risk of bias for this outcome.
4Downgraded one level due to imprecision: few events (N = 27) and wide 95% confidence interval.
5Downgraded one level due to imprecision: zero events reported in a narrative fashion.

Figures and Tables -
Summary of findings for the main comparison. Virus vaccines compared to placebo for preventing the common cold in healthy people
Comparison 1. Adenovirus vaccines versus placebo

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Incidence of the common cold Show forest plot

1

2307

Risk Ratio (M‐H, Fixed, 95% CI)

0.95 [0.45, 2.02]

Figures and Tables -
Comparison 1. Adenovirus vaccines versus placebo